Related Experiment Video

Updated: Aug 30, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Glycoprotein IIb-IIIa inhibitors in unstable coronary syndromes and percutaneous interventions--a conservative

Raffaele De Caterina1, Lorena Di Gioacchino

  • 1G. d'Annunzio University, Chieti, Italy.

Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology
|November 1, 2003
PubMed

Insights

Platelet glycoprotein IIb/IIIa antagonists are proven for percutaneous coronary interventions (PCI) but their use in unstable coronary syndromes without PCI remains debated. This review explores the ongoing discussion and identifies knowledge gaps.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Interventional Cardiology

Background:

  • Platelet glycoprotein IIb/IIIa antagonists are established therapies for preventing complications during percutaneous coronary interventions (PCI).
  • The efficacy and optimal use of these agents in unstable coronary syndromes (UCS) outside the context of PCI are subjects of ongoing clinical debate.

Purpose of the Study:

  • To summarize the rationale behind the current debate surrounding the use of glycoprotein IIb/IIIa antagonists in unstable coronary syndromes.
  • To identify and highlight key areas of uncertainty regarding their application in this patient population.

Main Methods:

  • Literature review and synthesis of existing clinical evidence and expert opinion.
  • Analysis of data from relevant clinical trials and observational studies.

Main Results:

  • Glycoprotein IIb/IIIa antagonists demonstrate clear benefits in acute settings like PCI, reducing thrombotic events.
  • Evidence for their benefit in unstable coronary syndromes managed without immediate PCI is less conclusive, with ongoing debate regarding risk-benefit profiles.

Conclusions:

  • While effective in PCI, the role of glycoprotein IIb/IIIa antagonists in non-PCI unstable coronary syndromes requires further clarification.
  • Addressing areas of uncertainty is crucial for optimizing treatment strategies and patient outcomes in cardiovascular medicine.

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Cardiac Catheterization IV: Nursing Management01:26

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...